Home › Trials › NCT05956418

Assessing Centhaquine for treating hypovolemic shock

A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock

Phase 4 Interventional Pharmazz, Inc. · NCT05956418

This study is testing if a new treatment called centhaquine can help adults with hypovolemic shock feel better and survive longer when used with standard care.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment400 (estimated)
Ages18 Years and up
SexAll
SponsorPharmazz, Inc. Industry-sponsored
Locations17 sites (Nellore, Andhra Pradesh and 16 other locations)
Trial IDNCT05956418 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and efficacy of centhaquine citrate, a novel treatment for hypovolemic shock, in approximately 400 adult patients. Participants will receive centhaquine alongside standard shock treatment, including fluid resuscitation and vasopressors, while being closely monitored throughout their hospitalization. The study aims to determine if centhaquine can improve blood pressure, reduce lactate levels, and ultimately decrease mortality rates in these patients. The drug works by enhancing venous return to the heart and producing arterial dilation, which may improve cardiac output during resuscitation.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with hypovolemic shock and a systolic blood pressure of 90 mmHg or lower upon hospital admission.

Not a fit: Patients with terminal illnesses unrelated to hypovolemic shock, altered consciousness, or those who have undergone CPR prior to enrollment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve outcomes for patients suffering from hypovolemic shock.

How similar studies have performed: While centhaquine has shown promise in animal models, this study represents a novel approach in human subjects for treating hypovolemic shock.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

• Adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\>2.0 mmol/L).

Exclusion Criteria

* Development of any other terminal illness not associated with hypovolemic shock during the study duration.
* Patient with altered consciousness not due to hypovolemic shock and comatose patient. • Known pregnancy.
* Cardiopulmonary resuscitation (CPR) before enrollment.
* Presence of a do not resuscitate order.
* Patient is participating in another interventional study.
* Patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure, or AIDS.

Where this trial is running

Nellore, Andhra Pradesh and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hypovolemic ShockShockHypovolemiaHemorrhageBlood PressureResuscitationCenthaquineAdrenergic
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.